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Abstract: Introduction: Infection caused by potentially oncogenic viruses, 
such as HPV and EBV, favors the role of certain oncoproteins that can induce 
dysplasias and malignant lesions. Objective: To evaluate the prevalence of 
HPV and EBV and their relation with the expression of p53 and PCNA in 
patients with oral carcinoma. Methodology: Twenty-seven oral squamous cell 
carcinomas (OSCC) were evaluated; DNA extraction was conducted using the 
QIAamp DNA mini kit; viral detection was obtained using the INNO-LiPA 
kit for HPV, and nested PCR was used for EBV. The evaluation of molecular 
markers was performed through immunohistochemical staining. Results: The 
mean age of the patients was 60.55±13.94 years, and 52% of these were female. 
Of the patients, 59% were tobacco users and 63% were alcohol consumers. 
HPV was detected in 70% of the patients with the predominance of genotype 
16 (60%). As for EBV infection, it was observed in 59% of cases. p53 and 
PCNA immunopositivity corresponded to 44% and 59%, respectively. The 
tongue was the anatomical location with highest positivity for both viruses as 
well as for the expression of molecular markers. The 48% of the cases presented 
infection by both viruses. Conclusion: HPV and EBV infection together with 
the expression of p53 and PCNA were more frequently observed in advanced 
stages of the disease, suggesting a more relevant role in the progression than in 
tumor genesis.
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INTRODUCTION.
Oral Squamous cell carcinomas (OSCCs) are a major public health 
problem. OSCCs occupy the twelfth position of all neoplams in the 
world, with an incidence that varies according to the region.1,2 In 
Venezuela, the mortality rate associated with cancer of the oral cavity 
represents 2.42% of the cancer cases, the tongue and gingiva being the 
areas with more frequent occurrence and mortality.3 
There are a number of risk factors including alcohol consumption 
and tobacco use, human papilloma virus (HPV) infection, poor oral 
hygiene, hereditary factors, herpes virus infection, advanced age, among 
others.4-6 HPV infection has been associated with approximately 25% of 
head and neck tumors. Although the transmission mechanism has not 
yet been clearly identified, HPV could be transmitted through sexual 
contact, the oral cavity being the entrance to the body.7 The Epstein-
Barr virus (EBV) is an oral herpes virus capable of inducing the onset 
of tumors related to some gene encoded proteins expressed in latent 
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infection.8 It has been detected in approximately 90% 
of the human population, with a tropism for epithelial 
and lymphoid cells.9
When these viral genes are expressed in cells infected 
with high risk oncogenic HPV or EBV, it favors 
oncoproteins, which can cause dysplasia and malignant 
epithelial lesions.10 A mutated form of p53 has been 
reported in two thirds of head and neck tumors, that 
increases resistance to treatment and leads to poor 
prognosis.11 Proliferating cell nuclear antigent (PCNA) 
has been linked to cell proliferation. As there is a clear 
relationship between these markers and the progression/
recurrence of cancer, they are used to predict the 
progression of tumors for the last few years.12
The aim of this study is to determine the prevalence 
of HPV and EBV infection and their relation to the 
expression of p53 and PCNA in patients with carcinoma 
of the oral cavity.
MATERIALS AND METHODS.
Design and subjects
Twenty-seven patients with histological diagnosis 
of OSCC treated at the Head and Neck Service of the 
Oncologic Hospital “Padre Machado” (IVSS, Caracas, 
Venezuela) were evaluated in the study.
Fresh biopsies were obtained and cut into two sec-
tions; one was frozen for molecular biology analysis 
and the other fragment was embedded in paraffin to be 
used in histological diagnosis and immunohistochemi-
cal tests. 
Clinical information was obtained from medical 
records. This study included all patients who were 
diagnosed with OSCC at the health service and who 
voluntarily agreed to participate in the study. Immu-
nosuppressed patients who had received radiotherapy 
or chemotherapy treatment prior to the sampling were 
excluded.
Bioethical considerations 
A written informed consent was signed by all patients, 
expressing their approval to participate in the study. 
In addition they completed a survey evaluated and 
approved by the Bioethics Committee of the Institute 
of Biomedicine, which is included in the FONACIT 
funded research projects registered under the numbers 
G-2005000408, 2013000413, and Misión Ciencia 
project number 20074001088.
DNA extraction
DNA was extracted using the QIAamp DNA mini 
kit (QIAGEN®, Germany), following the manufacturer’s 
specifications. Biopsies were cut and incubated in ATL 
buffer at 65°C overnight, and subsequently buffer AL 
was added and incubated at 70°C for 10 min. Absolute 
ethanol was added and the lysate was transferred to 
a column. The elution was performed with 200μl of 
elution buffer. The resulting DNA samples were stored 
at -80°C until use.
HPV detection
HPV detection was conducted with the INNO-LiPA 
Genotyping Extra commercial kit (Innogenetics, Bel-
gium), following the manufacturer’s specifications. The 
test is based on a Polymerase chain reaction (PCR) in 
which a fragment of the L1 region of the viral genome is 
amplified using the biotinylated SPF10 primers. Biotin-
ylated amplicons are subsequently hybridized with im-
mobilized oligonucleotides as parallel lines on nitroce-
llulose strips. Following the hybridization and stringent 
washes, the streptavidin conjugate was added and the 
strips were incubated with alkaline phosphatase. The 
incubation with BCIP/NBT chromogen leads to forma-
tion of a purple precipitate in cases where hybrids are 
formed and results are visually interpreted. 
Epstein-Barr virus detection 
Epstein-Barr virus detection was carried out by 
a nested PCR with W1 and W2 primers in the first 
round of amplification, and W3 and W4 primers for 
the second round of amplification (Table 1) as described 
by Arreaza et al.,13 resulting in 192bp product. A 
negative control (reaction mixture + distilled water) 
was also included. In both rounds of amplification 
of the EBV, the PCR mixture consisted of 2.5μl of 
DNA in 25μl of reaction mix containing 10mmol/l 
tris-HCL (pH 8.3) (Invitrogen, USA), 50mmol/l KCL 
(Invitrogen, USA), 1.2mmol/l MgCl2 (Invitrogen, 
USA), 200μmol/l of each dNTP (Invitrogen, USA), 
20pmol of each respective primer (Invitrogen, USA), 
1.25U of Taq polymerase (Invitrogen, USA) and water. 
With the external primers, 30 cycles of amplification 
were performed: at 92°C for 45 seconds, at 66°C for 30 
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seconds and at 72°C for 45 seconds. From the amplified 
material, 2.5μl were used to amplify the DNA with the 
internal primers, using 40 PCR cycles. The results of 
the amplification were visualized by electrophoresis on 
a 3% agarose gel, in 1X TBE buffer (Invitrogen, USA). 
The gels were stained with ethidium bromide (0.2μl of 
1% solution) and exposed to UV light (ChemiDOCTM 
XRS +. BIORAD, USA) for photographic recording.
Immunohistochemistry 
Exposure of the antigen was performed in citrate bu-
ffer, and the endogenous peroxidase was blocked using 
3% H2O2 in methanol. The sections were incubated in 
a 1:100 dilution of the primary monoclonal antibody 
against p53 or PCNA (Invitrogen, USA). Incubation was 
performed with a secondary IgG antibody (anti-mouse), 
followed by another incubation with the ABC complex 
kit (Vectastain, Mexico). The detection was performed 
with amino-ethyl-carbazole. The sections were finally 
stained with hematoxylin and rinsed with running wa-
ter. A scale of one to three crosses (+) for positive and 
(-) for negative was used to score the tissue samples. 
The number of crosses symbolizes the intensity (I) and 
the extension (E) of the observed tissue. This code was 
used for the extension (E) as follows: +: few labeled cells 
(≥25%); ++: 50% - 75% of labeled cells; +++: >75% of la-
beled cells. Regarding intensity of labeling, the number 
of crosses were used as follows: +: weakly labeled cells; 
++: moderately labeled cells; +++: strongly labeled cells.
          Primer Sequence Amplification Round 
 W1 5´CTA GGG GAG AAC GTG AA 3´ First
 W2 5´ CTG AAG GTG AAC CGC TTA CCA 3´ First
 W3 5´ GGT ATC GGG CCA GAG GTA AGT 3´ Second
 W4 5´ GCT GGA CGA GGA CCC TTC TAC 3´ Second
Table 1. Sequence of primers for EBV detection.
Detection of  Viral Infection  Percentage of patients (%)
VPH  Positive 70
  Negative 30 
Genotypes 16 60
  Other genotypes 40
      Other high risk genotypes 62
    Other low risk genotypes 38 
Tumor Location Tongue 56
       Floor of the Mouth 16
       Alveolar Ridge 16
       Lip 6
      Oral Mucosa 6 
EBV  Positive 59
  Negative 41 
Tumor Location Tongue 44
       Alveolar Ridge 18
      Lip 13
       Floor of the Mouth 13
       Oral Mucosa 6
       Hard Palate 6
Table 2. Detection of viral infections according to genotype and location.
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   Positivity rate
Stage                               p53 (%) PCNA (%) VPH (%)  VEB (%)
 I 7 7 3 0
 II 0 11 7 7
 III 11 19 18 26
 IV 26 22 40 26
Table 3. Viral Infections and p53 and PCNA expression according to Tumor Stage . 
RESULTS.
The mean age of the patients was 60.55±13.94 years, and 
52% were female. Of the patients, 59% were tobacco us-
ers and 63% were alcohol consumers. The tongue was the 
most frequent location of the tumor (55%), followed by 
the floor of the mouth and alveolar ridge (15% each), 7% 
corresponded to carcinoma of the lip, while tumors in the 
oral mucosa and hard palate were both detected in 4% of 
the evaluated patients.
Most of the identified tumors were at an advanced 
stage: 52% stage IV, 30% stage III, 11% stage II and only 
at 7% stage I.
Table 2 shows the distribution of HPV and EBV accord-
ing to genotype and anatomical location. In the evaluated 
samples, 67% of which corresponded to the tongue tissue, 
PCNA was the marker that showed the highest immu-
nopositivity, up to 59%. The p53 gene was detected in 44% 
of the cases, 75% of which corresponded to tongue tissue. 
Table 3 shows the distribution of viral infections and the 
expression of p53 and PCNA according to the tumor stage.
DISCUSSION.
An important factor in OSCC is age, which in this 
study remained within the described range, the fifth and 
seventh decade of life.14 However, Majchrzak et al.,15 
suggested that there will be an increase in OSCC incidence 
in young adults in the coming years. The development 
of this malignancy was observed mainly in females, and 
can be explained by the recent involvement of women in 
risky health practices. The anatomical location with the 
highest occurrence of tumors was the tongue, similar to 
what was reported by Hübber et al.,16 who suggested that 
the most frequent locations of the tumors were the tongue, 
lips, gingiva and hard palate. This is also consistent with 
several other studies reporting the occurrence of tumors 
in lips, tongue, gingiva, floor of the mouth and palate in 
descending order.15
A high percentage of the samples were positive for 
HPV infection, which coincides with studies carried out 
by Veitía et al.,17 who reported that 66.7% of Venezuelan 
patients with head and neck tumors were positive for 
this virus, with the highest infection rate found in the 
oral cavity. Studies worldwide show similar results, 
for example Kreimer et al.,18 suggest the oral cavity is 
the anatomical location with the greatest tendency to 
develop these kinds of tumors, also being a location 
with the highest rate of HPV infection.
In this study, a high percentage of HPV positive patients 
were alcohol and tobacco users, which is non consistent 
with the literature, since patients with HPV-associated 
cancers do not present these risk factors. However, a meta-
analysis performed by Dayyani et al.,19 observed that 55% 
of OSCC-positive HPV patients are tobacco users and 
66% are alcohol consumers. In addition, Kumar et al.,5 
indicate that there is a statistically significant association 
between high risk HPV infection (genotypes 16 and 18) 
and alcohol and tobacco use in patients with squamous 
cell carcinoma of the head and neck. Therefore, risk 
factors for HPV infection and other viral infections 
may act synergistically in the development process and 
progression of the malignancy. HPV-16 was the most 
frequent genotype observed in this study, either as a single 
infection or together with other viral genotypes. Dufour 
et al.,20 described that the detection of head and neck 
viral loads differs greatly and varies according to the type 
of sample and technique used, but the HPV genotype 16 
is still the most frequently detected.22,23
EBV is transmitted through saliva contact and initially 
infects and replicates in the stratified squamous epithelium 
of the upper aerodigestive tract.24 In this study, EVB 
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was detected in over half of the samples, which coincides 
with other studies, emphasizing that the virus positivity 
rate varies according to the methodology used for its 
detection.25 Jirbil et al.,26 suggest that EBV is strongly 
linked to the development of nasopharyngeal, tongue, and 
salivary gland cancer, among others, areas in  the upper 
aerodigestive tract. In Venezuela, Veitía et al.,27 reported 
a 44% rate of EBV infection, and 28% positive cases for 
the the virus in the oral cavity. Similarly, Kis28 observed 
that 66% of the patients evaluated were EBV positive, the 
majority of which corresponded to large tumors, which 
was related to a decrease in patient survival.
EBV-HPV co-infection was observed in half of the 
samples, which supports the hypothesis of Kumar et al.,5 
which proposes that infection by multiple oncogenic viral 
agents acts as an important risk factor in oral carcinoma. 
Similarly, Jiang et al.,29 suggest that co-infection may have 
a bigger effect on invasion than on proliferation.
In this study, p53 and PCNA expression were mainly 
observed in an advanced stage of the disease, and the most 
frequent anatomical location was the tongue. According 
to previous reports, p53 expression is observed in 62% 
of cases of invasive carcinoma of the oral cavity, whereas 
PCNA was observed in 100% of the evaluated cases.20
Stage III tumors had a higher PCNA expression, 
which is consistent with the literature.14 Kupiz et al.,12 
reported 100% of PCNA expression in primary tumors 
and metastatic head and neck lymph nodes. This marker 
could be useful for evaluating the aggressiveness of a 
tumor, since the percentage of immunopositive cells for 
PCNA is significantly higher in primary tumors associ-
ated to metastasis.
CONCLUSION.
HPV and EBV infection, as well as p53 and PCNA 
expression, were observed more frequently in advanced 
stages of the disease, suggesting a more relevant role in 
progression than in tumor genesis.
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